肝细胞肝癌患者血清LG2m和hPG80表达水平及临床价值研究  

Study on the Expression Levels and Clinical Value of Serum LG2m and hPG80 in Patients with Hepatocellular Carcinoma

作　　者：刘宏 张春华 阳宏 王万琴 LIU Hong;ZHANG Chunhua;YANG Hong;WANG Wanqin(Department of Gastroenterology,the First People’s Hospital of Shuangliu District/West China Airport Hospital of Sichuan University,Chengdu 610200,China)

机构地区：[1]成都市双流区第一人民医院/四川大学华西空港医院消化内科,成都610200

出　　处：《现代检验医学杂志》2024年第1期83-89,共7页Journal of Modern Laboratory Medicine

基　　金：四川省医学卫生健康科研课题(19PJ065):肝细胞肝癌(HCC)患者血清LG2m,hPG80的水平及临床意义。

摘　　要：目的研究肝细胞肝癌(hepatocellular carcinoma,HCC)患者血清层黏连蛋白γ2单体(laminin gamma 2monomer,LG2m)、人循环前胃泌素(human circulating gastrin,hPG80)表达水平及临床价值。方法选取2016年1月~2018年1月成都市双流区第一人民医院收治的128例HCC患者为HCC组,以同期诊治的70例肝脏良性病变患者为良性病变组,以同期体检的70例健康人为对照组。应用酶联免疫吸附试验检测血清LG2m和hPG80水平。受试者工作特征(ROC)曲线分析血清LG2m和hPG80对HCC患者预后的评估价值。Kaplan-Meier生存分析比较不同血清LG2m和hPG80水平HCC患者生存预后差异。COX回归分析影响HCC患者预后的因素。结果HCC组血清LG2m(28.14±3.10ng/L),hPG80(84.83±11.39 ng/L)水平高于良性病变组(9.18±1.74 ng/L,25.10±4.11 ng/L)和对照组(8.24±1.65ng/L,23.15±3.26 ng/L),差异具有统计学意义(t=68.240~76.635,均P<0.05)。TNM分期Ⅲ期、低分化程度、血清AFP>400μg/L患者血清LG2m,hPG80水平高于TNM分期I~Ⅱ期、高中分化程度、AFP≤400μg/L患者,差异具有统计学意义(t=3.216~13.552,均P<0.05)。血清LG2m,hPG80联合检测对HCC患者预后评估的曲线下面积(95%CI)为0.934(0.889~0.961),大于单项指标检测0.813(0.774~0.849),0.896(0.840~0.937)。血清LG2m高表达和低表达HCC患者的五年总体生存率分别为33.33%(21/63),67.69%(44/65)。与血清LG2m低表达HCC患者相比,血清LG2m高表达HCC患者五年累积生存率更低(Log-Rankχ^(2)=19.522,P<0.05)。血清hPG80高表达和低表达HCC患者的五年总体生存率分别为35.48%(22/62),65.15%(43/66)。与血清hPG80低表达HCC患者相比,血清hPG80高表达HCC患者五年累积生存率更低(Log-Rankχ^(2)=12.546,P<0.05)。TNM分期Ⅲ期(OR=1.487,P<0.05)、低分化程度(OR=1.611,P<0.05)、血清AFP≥400μg/L(OR=1.416,P<0.05)、血清LG2m(OR=1.838,P<0.05)高表达、hPG80(OR=1.735,P<0.05)高表达是HCC患者不良预后的独立危险因素。结论HCC患者血清LG2m和hPG80水平升Objective To study the serum lamininγ2 monomer(LG2m),human circulating Gastrin(hPG80)in patients with hepatocellular carcinoma(HCC)and their clinical value.Methods 128 HCC patients admitted to the First People’s Hospital of Shuangliu District from January 2016 to January 2018 were selected as the HCC group,70 patients with benign liver lesions diagnosed and treated at the same time were selected as the benign lesion group,and 70 healthy individuals who underwent physical examinations during the same time were selected as the control group.Use enzyme-linked immunosorbent assay to detect serum LG2m and hPG80 levels.The evaluation value of serum LG2m and hPG80 in predicting the prognosis of HCC patients were analyzed by receiver operating characteristic curve.Kaplan-Meier survival analysis was used to compare the survival prognosis of HCC patients with different serum LG2m and hPG80 levels.COX regression analysis was used to analyze the prognostic factors of HCC patients.Results The levels of serum LG2m(28.14±3.10 ng/L),hPG80(84.83±11.39 ng/L)in the HCC group were higher than those in the benign lesion group(9.18±1.74 ng/L,25.10±4.11 ng/L)and the control group(8.24±1.65 ng/L,23.15±3.26 ng/L),and the differences were statistically significant(t=68.240~76.635,all P<0.05).The levels of serum LG2m and hPG80 in patients with TNM stage III,low differentiation degree,serum AFP>400μg/L were higher than those in TNM stage I to II,high differentiation,AFP≤400μg/L,the differences were statistically significant(t=3.216~13.552,all P<0.05).The area under the curve(95%CI)of the combined evaluation of serum LG2m and hPG80 for the prognosis of HCC patients was 0.934(0.889~0.961),which was greater than the single indicator of 0.813(0.774~0.849)and 0.896(0.840~0.937).The overall 5-year survival rates of HCC patients with high and low serum LG2m expression were 33.33%(21/63)and 67.69%(44/65),respectively.Compared with HCC patients with low expression of serum LG2m,HCC patients with high expression of serum LG2m had a lower

关 键 词：肝细胞肝癌 层黏连蛋白γ2单体 人循环前胃泌素 

分 类 号：R735.7[医药卫生—肿瘤] R730.43[医药卫生—临床医学]